Royal London Asset Management Ltd. Boosts Stake in Boston Scientific Co. (NYSE:BSX)

Royal London Asset Management Ltd. raised its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 635,079 shares of the medical equipment provider's stock after purchasing an additional 22,525 shares during the quarter. Royal London Asset Management Ltd.'s holdings in Boston Scientific were worth $53,220,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Triad Wealth Partners LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Values First Advisors Inc. bought a new stake in Boston Scientific during the third quarter valued at about $28,000. Andra AP fonden purchased a new position in shares of Boston Scientific in the second quarter valued at about $29,000. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Boston Scientific in the third quarter worth about $30,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Boston Scientific during the third quarter worth about $30,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company's stock, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at $133,046,484.48. The trade was a 9.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 328,157 shares of company stock valued at $27,957,676 in the last 90 days. Company insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Royal Bank of Canada boosted their price target on Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Sanford C. Bernstein raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Citigroup boosted their price target on shares of Boston Scientific from $92.00 to $98.00 and gave the stock a "buy" rating in a research note on Thursday, October 24th. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Monday, November 4th. Finally, TD Cowen raised their price target on Boston Scientific from $86.00 to $100.00 and gave the company a "buy" rating in a report on Monday, October 21st. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and an average target price of $93.39.

Boston Scientific Trading Down 0.5 %

Shares of NYSE:BSX traded down $0.46 during trading hours on Friday, hitting $90.07. 3,021,319 shares of the company's stock traded hands, compared to its average volume of 6,012,767. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The business has a fifty day moving average price of $87.27 and a 200-day moving average price of $81.16. Boston Scientific Co. has a 1 year low of $54.52 and a 1 year high of $91.93. The firm has a market capitalization of $132.75 billion, a P/E ratio of 74.44, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the company posted $0.50 EPS. Boston Scientific's quarterly revenue was up 19.3% on a year-over-year basis. Equities analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.